Bon Natural Life’s Subsidiary Secures Exclusive Sales Partnership with Beijing Huahai Keyuan

An update from Bon Natural Life ( (BON) ) is now available.

On April 15, 2025, Bon Natural Life Limited’s subsidiary, Xi’an App-Chem Bio (Tech) Co., Ltd, entered into a cooperation agreement with Beijing Huahai Keyuan (Tech) Co., Ltd. Under this agreement, Beijing Huahai Keyuan will become the exclusive sales partner for App-Chem’s postbiotic health product line, which includes a hypoglycemic patented ingredient. The agreement, which spans 36 months, guarantees a minimum of $32 million in sales and outlines responsibilities for product manufacturing, quality control, and sales activities. This partnership is expected to enhance App-Chem’s market presence and leverage Beijing Huahai Keyuan’s expertise in brand management and market expansion.

Spark’s Take on BON Stock

According to Spark, TipRanks’ AI Analyst, BON is a Neutral.

Bon Natural Life faces significant financial challenges, with declining revenues and negative cash flows. Technical indicators further highlight bearish momentum. Despite a low P/E ratio suggesting potential undervaluation, the company’s liquidity issues and lack of dividend yield are key risks, resulting in an overall score of 51.

To see Spark’s full report on BON stock, click here.

More about Bon Natural Life

Bon Natural Life Limited, through its subsidiary Xi’an App-Chem Bio (Tech) Co., Ltd, is a Nasdaq-listed company specializing in the supply of natural bioactive ingredients and health solutions. The company focuses on researching, developing, producing, and selling natural active ingredients for personal health and care products. Its products are distributed globally, including in China, Japan, South Korea, the United States, and the European Union.

Average Trading Volume: 40,217,969

Technical Sentiment Signal: Sell

Current Market Cap: $292.2K

See more data about BON stock on TipRanks’ Stock Analysis page.